CoChat

Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing

The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.

Abstract

Previous studies have suggested that elderly men eliminate alprazolam more slowly than young adults. This study in the elderly was designed to determine whether a change in pharmacokinetics influences the response to alprazolam during multiple dose regimens. In addition, the study was designed to determine alprazolam pharmacokinetics and the degree to which its hydroxymetabolites accumulate, the degree of psychomotor impairment, and whether tolerance to impairment and sedation develops during three different multiple dose regimens. Twenty-six subjects completed this study. The subjects were randomized into one of three treatment groups: 0.25 mg q8h, 0.5 mg q8h, and 2 mg q12h. Subjects remained in the clinic for 8 days (day -2-day 5). Day 0 was used as a drug free testing day to establish baseline scores for sedation, digit symbol substitution (DSS), card sorting (CS) tasks, and two computer tests. Subjects received the drug according to schedule on days 1 through 4, with day 5 as the washout day. Blood samples were assayed for alprazolam, alpha-hydroxyalprazolam and 4-hydroxyalprazolam. Alpha-hydroxyalprazolam concentrations were below assay detection limits in all subjects in the 0.25 and 0.5 mg q8h groups and less than or equal to 2.6 ng/ml in the 2 mg q12h group. When detectable, 4-hydroxyalprazolam concentrations were less than 10% of the corresponding alprazolam concentration. Mean alprazolam oral clearance values in the three treatment groups ranged between 0.54 and 0.62 ml/min/kg and half-lives were in excess of 21 h. Degree of sedation and impairment was dose related. Sedation and impairment was not higher on day 4 despite concentrations 2-3 times as great as on day 1, indicating development of tolerance. Subjects were not, however, back to baseline level of performance on day 4.

Overview

Integrity signals

Registry

Crossref · 10.1007/bf02243999

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 4

  1. Barnhill BM, Lyon JA (1984) Micrononlin for MS-DOS computers. Nonlinear regression analysis, version 1.0. Elite Software, Pittsburgh, PA
  2. Derry CL, Hamilton JM, Etheridge JF, Koett SL, Smith RB, Kroboth PD (1987) Effect assessment for sedative drugs: method validation and application to triazolam. Abstract Pharm Res 4(S):100
  3. Eberts FS, Philopoulos Y, Reineke LM, Vliek RW (1980) Disposition of14C-alprazolam, a new anxiolytic-antidepressant, in man. Abstract Pharmacologist 22:279
  4. SAS Institute Inc (1985) User's Guide: Statistics, Version 5th edn. SAS Institute Inc, Cary, NC

Cited by

See all 36

Metadata

Authors
Kroboth, P. D., McAuley, J. W., & Smith, R. B.
Affiliations
University of Pittsburgh (US)
Venue
Psychopharmacology
Published
1990-04
Volume
100
Issue
4
Pages
477-484
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W2000112742
Cited by
35
References
21
Citations by year
2026: 1 · 2021: 1 · 2018: 1
FWCI
2.85
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
alprazolam, older adults, pharmacokinetics, pharmacodynamics, repeated dosing, drug metabolites, sedation, psychomotor impairment, tolerance (pharmacology and immunology), oral clearance, half-life
MeSH terms
Aged, Aged, 80 and over, Alprazolam, Biotransformation, Drug Tolerance, Female, Half-Life, Humans, Hypnotics and Sedatives, Male, Psychomotor Performance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.